JP5118851B2 - 線維芽細胞増殖因子フラグメントの使用 - Google Patents

線維芽細胞増殖因子フラグメントの使用 Download PDF

Info

Publication number
JP5118851B2
JP5118851B2 JP2006538755A JP2006538755A JP5118851B2 JP 5118851 B2 JP5118851 B2 JP 5118851B2 JP 2006538755 A JP2006538755 A JP 2006538755A JP 2006538755 A JP2006538755 A JP 2006538755A JP 5118851 B2 JP5118851 B2 JP 5118851B2
Authority
JP
Japan
Prior art keywords
fgf
fragment
expression
polypeptide
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006538755A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007521799A (ja
JP2007521799A5 (https=
Inventor
ジャック・ボルカン
サラ−ディーヌ・シブー
ジャッキー・ヴォンデルシェ
フランソワ・ルゲイ
アンドレ・コルディエ
ルーベン・パポイアン
アンドレアス・シェーラー
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2007521799A publication Critical patent/JP2007521799A/ja
Publication of JP2007521799A5 publication Critical patent/JP2007521799A5/ja
Application granted granted Critical
Publication of JP5118851B2 publication Critical patent/JP5118851B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
JP2006538755A 2003-11-07 2004-11-05 線維芽細胞増殖因子フラグメントの使用 Expired - Fee Related JP5118851B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51807303P 2003-11-07 2003-11-07
US60/518,073 2003-11-07
US57224704P 2004-05-18 2004-05-18
US60/572,247 2004-05-18
PCT/EP2004/012572 WO2005045044A2 (en) 2003-11-07 2004-11-05 Use of fibroblast growth factor fragments

Publications (3)

Publication Number Publication Date
JP2007521799A JP2007521799A (ja) 2007-08-09
JP2007521799A5 JP2007521799A5 (https=) 2007-12-13
JP5118851B2 true JP5118851B2 (ja) 2013-01-16

Family

ID=34576820

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006538755A Expired - Fee Related JP5118851B2 (ja) 2003-11-07 2004-11-05 線維芽細胞増殖因子フラグメントの使用

Country Status (7)

Country Link
US (3) US20090093398A1 (https=)
EP (1) EP1682665B1 (https=)
JP (1) JP5118851B2 (https=)
AT (1) ATE507296T1 (https=)
DE (1) DE602004032457D1 (https=)
ES (1) ES2365852T3 (https=)
WO (1) WO2005045044A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
JP2006347979A (ja) * 2005-06-17 2006-12-28 National Institute Of Advanced Industrial & Technology 創傷治療及び／又は創傷治癒促進のための薬剤
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US11308462B2 (en) 2014-05-13 2022-04-19 Clear Token Inc Secure electronic payment
JP6232689B2 (ja) 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
WO2021075535A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 異常幹細胞を標的とする糖尿病治療
US20230382966A1 (en) * 2020-10-27 2023-11-30 Indiana University Research And Technology Corporation Novel klotho interaction site in the c-terminus of fgf23
CN114940990B (zh) * 2022-06-20 2023-03-14 北京市神经外科研究所 与颅内动脉瘤相关的基因突变位点及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249125A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US20030105302A1 (en) * 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
ES2340662T3 (es) * 2000-07-19 2010-06-08 Advanced Research And Technology Institute Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
AU2002214286A1 (en) * 2000-11-15 2002-05-27 Akiko Itai Method of profiling protein
JP2002223753A (ja) * 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
CA2443719A1 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
EP1491628A4 (en) * 2002-03-29 2006-10-18 Nat Inst Of Advanced Ind Scien NEW GALACTOSTRANSFERASES, PEPTIDES AND THESE CODING NUCLEIC ACID
JPWO2003091427A1 (ja) * 2002-04-24 2005-09-02 関西ティー・エル・オー株式会社 近位尿細管に発現する腎疾患関連遺伝子群

Also Published As

Publication number Publication date
ES2365852T3 (es) 2011-10-11
US20090093398A1 (en) 2009-04-09
JP2007521799A (ja) 2007-08-09
EP1682665B1 (en) 2011-04-27
ATE507296T1 (de) 2011-05-15
WO2005045044A3 (en) 2005-11-10
US20130040882A1 (en) 2013-02-14
EP1682665A2 (en) 2006-07-26
HK1095160A1 (en) 2007-04-27
WO2005045044A2 (en) 2005-05-19
US20120028896A1 (en) 2012-02-02
DE602004032457D1 (de) 2011-06-09

Similar Documents

Publication Publication Date Title
US20120028896A1 (en) Use of fibroblast growth factor fragments
Carpenter et al. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors
AU2014296288B2 (en) Compositions and methods for modulating thermogenesis using PTH-related and EGF-related molecules
JP2003531583A (ja) ヒトｆｇｆ−２３遺伝子および遺伝子発現産物
CA2365449A1 (en) Inhibitor of the growth of androgen-independent tumor
US20220017938A1 (en) Methods of identifying drug-modulated polypeptide targets for degradation
Grill et al. Parathyroid hormone-related protein (PTHrP) and hypercalcaemia
JP2003523190A (ja) 新規化合物
CN109517898B (zh) 一种食管癌检测、诊断或者预后评价制剂，治疗食管癌的药物及rnd2基因的应用
Moin et al. Effectiveness of analog of Humanin in ameliorating streptozotocin-induced diabetic nephropathy in Sprague Dawley rats
WO2002101002A2 (en) Identification of snps the hgv-v gene
CN101784674A (zh) Egfr抑制剂治疗的预测性标记物
JP5012566B2 (ja) インスリン抵抗性マーカー
HK1095160B (en) Use of fibroblast growth factor fragments
JP2002530110A (ja) 哺乳動物のウロテンシンｉｉ及びその応用
US20030165977A1 (en) Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism
JP2007518702A (ja) ソマトスタチン類似体処置の効力についてのバイオマーカー
EP3715473A1 (en) Prognostic markers, therapeutic target and treatment for acromegaly
CN113289002A (zh) 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
Acton Anterior Pituitary Hormones—Advances in Research and Application: 2012 Edition
KR20070094785A (ko) 암, 특히 직장결장암 치료에서의 표적으로서의포스포리파제 ａ2의 확인 및 이의 작용 메카니즘
CN113604561B (zh) Sf3b1基因突变在混合性prl阳性垂体腺瘤辅助诊断中的应用
Nelson et al. Tumor expression studies indicate that HEM-1 is unlikely to be the active factor in oncogenic osteomalacia
Turki et al. The Potential Roles of 77C> T Variant and Growth Hormone-Releasing Hormone Elevation in Pituitary Adenoma Cases Associated with Acromegaly
Lu et al. The NR5A1 mutation was identification in male infertility

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100727

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120807

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120905

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20121002

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20121022

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20151026

Year of fee payment: 3

LAPS Cancellation because of no payment of annual fees